Sunshine Biopharma gets 180-day Nasdaq bid-price compliance extension to March 18, 2024

Sunshine Biopharma Inc.

Received 180-day Nasdaq extension until March 18, 2024 to meet $1.00 min bid price.
Company meets all other continued listing requirements except bid price.
Intends to cure deficiency, potentially via reverse stock split if necessary.
No immediate effect on listing or trading; common stock continues on Nasdaq under 'SBFM'.
Compliance can be regained if closing bid price ≥$1.00 for 10 consecutive business days before deadline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.